Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor In 5 of 46 patients (10.9%) at their center, Hatcher and colleagues1 reported “unexpectedly severe clinical relapses” that they described as “clinical rebound syndrome confirmed on magnetic resonance imaging within 4 to 16 weeks after ceasing fingolimod treatment” for multiple sclerosis. The postulated frequency of “rebound” is intriguing, and we agree with the authors that it is clinically relevant to carefully evaluate and treat patients who discontinue a disease-modifying treatment. However, we wish to express our concerns about the conclusions drawn from this small uncontrolled sample, given that the data contrast strongly with those from a thorough evaluation in a large controlled data set on fingolimod.2,3
Merschhemke M, Tomic D, Putzki N. Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation. JAMA Neurol. 2016;73(11):1375. doi:10.1001/jamaneurol.2016.3199
Customize your JAMA Network experience by selecting one or more topics from the list below.